Department of Traumatology, MRI, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675, Munich, Germany.
J Mater Sci Mater Med. 2011 May;22(5):1087-99. doi: 10.1007/s10856-011-4306-7. Epub 2011 Apr 3.
Although significant progress has been made in the field of orthotopic liver transplantation, cell-based therapies seem to be a promising alternative to whole-organ transplantation. The reasons are manifold but organ shortage is the main cause for this approach. However, many problems such as the question which cell type should be used or which application site is best for transplantation have been raised. In addition, some clinicians have had success by cultivating liver cells in bioreactors for temporary life support. Besides answering the question which cell type, which injection site or even which culture form should be used for liver support recent international harmonization of legal requirements is needed to be addressed by clinicians, scientists and companies dealing with cellular therapies. We here briefly summarize the possible cell types used to partially or temporarily correct liver diseases, the most recent development of bioreactor technology and important regulatory issues.
尽管在原位肝移植领域取得了重大进展,但细胞疗法似乎是一种有前途的替代整体器官移植的方法。原因有很多,但器官短缺是这种方法的主要原因。然而,已经提出了许多问题,例如应该使用哪种细胞类型或哪种应用部位最适合移植。此外,一些临床医生通过在生物反应器中培养肝细胞来进行临时生命支持已经取得了成功。除了回答应该使用哪种细胞类型、哪种注射部位甚至哪种培养形式来进行肝脏支持的问题外,处理细胞疗法的临床医生、科学家和公司还需要解决最近国际上对法律要求的协调问题。我们在这里简要总结了用于部分或临时纠正肝脏疾病的可能细胞类型、生物反应器技术的最新发展和重要的监管问题。